WallStreetZenWallStreetZen

NASDAQ: SYRE
Spyre Therapeutics Inc Stock Ownership - Who owns Spyre Therapeutics?

Insider buying vs selling

Have Spyre Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Cameron TurtleChief Executive Officer2024-02-15400$9.82
$3.93kBuy

1 of 1

SYRE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SYRE insiders and whales buy or sell their stock.

SYRE Shareholders

What type of owners hold Spyre Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC29.49%10,662,080$318.80MInsider
Fmr LLC10.47%3,785,877$113.20MInstitution
Baker Bros Advisors LP8.56%3,094,590$92.53MInsider
Orbimed Advisors LLC7.83%2,829,748$84.61MInsider
Perceptive Advisors LLC7.21%2,606,679$77.94MInstitution
Vr Adviser LLC6.56%2,372,714$70.94MInstitution
Rtw Investments LP6.18%2,232,760$66.76MInstitution
Novartis Bioventures Ltd6.02%2,175,314$65.04MInsider
Deep Track Capital LP5.40%1,952,760$58.39MInstitution
Commodore Capital LP5.21%1,884,084$56.33MInstitution

1 of 3

SYRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SYRE55.87%44.13%Net BuyingNet Buying
TARS66.47%33.53%Net SellingNet Selling
MNKD30.01%69.99%Net BuyingNet Buying
MGNX72.48%27.52%Net BuyingNet Selling
ETNB85.94%14.06%Net BuyingNet Selling

Spyre Therapeutics Stock Ownership FAQ

Who owns Spyre Therapeutics?

Spyre Therapeutics (NASDAQ: SYRE) is owned by 77.48% institutional shareholders, 61.21% Spyre Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Spyre Therapeutics shareholder, owning 10.66M shares representing 29.49% of the company. Fairmount Funds Management LLC's Spyre Therapeutics shares are currently valued at $372.85M.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.